SI9200410B - Nove tetrahidroizokinolinove spojine - Google Patents
Nove tetrahidroizokinolinove spojine Download PDFInfo
- Publication number
- SI9200410B SI9200410B SI9200410A SI9200410A SI9200410B SI 9200410 B SI9200410 B SI 9200410B SI 9200410 A SI9200410 A SI 9200410A SI 9200410 A SI9200410 A SI 9200410A SI 9200410 B SI9200410 B SI 9200410B
- Authority
- SI
- Slovenia
- Prior art keywords
- carbon atoms
- formula
- phenyl
- compounds
- methyl
- Prior art date
Links
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract 14
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 12
- -1 polyhaloalkoxy Chemical group 0.000 claims abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 9
- 125000001424 substituent group Chemical group 0.000 claims abstract 6
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 4
- 125000006684 polyhaloalkyl group Polymers 0.000 claims abstract 4
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract 3
- 230000036592 analgesia Effects 0.000 claims abstract 3
- 206010013663 drug dependence Diseases 0.000 claims abstract 3
- 208000011117 substance-related disease Diseases 0.000 claims abstract 3
- 208000011580 syndromic disease Diseases 0.000 claims abstract 3
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 2
- 125000002947 alkylene group Chemical group 0.000 claims abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 2
- 201000000980 schizophrenia Diseases 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- IODKIOZUVXRIIM-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)cyclopropyl]-6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol 1-[1-(2-chlorophenyl)cyclopropyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol Chemical compound ClC1=C(C=CC=C1)C1(CC1)C1N(CCC2=CC(=C(C=C12)O)F)C.ClC1=C(C=CC=C1)C1(CC1)C1N(CCC2=CC(=C(C=C12)O)OC)C IODKIOZUVXRIIM-UHFFFAOYSA-N 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- HBVDEXCJALUQMJ-UHFFFAOYSA-N [1-[1-(2-chlorophenyl)cyclopropyl]-6-fluoro-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl] decanoate Chemical compound CN1CCC=2C=C(F)C(OC(=O)CCCCCCCCC)=CC=2C1C1(C=2C(=CC=CC=2)Cl)CC1 HBVDEXCJALUQMJ-UHFFFAOYSA-N 0.000 claims 1
- VBKOIMOYANNPFE-UHFFFAOYSA-N [1-[1-(2-chlorophenyl)cyclopropyl]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl] hexadecanoate Chemical compound CN1CCC=2C=C(OC)C(OC(=O)CCCCCCCCCCCCCCC)=CC=2C1C1(C=2C(=CC=CC=2)Cl)CC1 VBKOIMOYANNPFE-UHFFFAOYSA-N 0.000 claims 1
- ZVXVWCGNWQEEMF-UHFFFAOYSA-N [1-[1-(2-chlorophenyl)cyclopropyl]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl] octadecanoate Chemical compound CN1CCC=2C=C(OC)C(OC(=O)CCCCCCCCCCCCCCCCC)=CC=2C1C1(C=2C(=CC=CC=2)Cl)CC1 ZVXVWCGNWQEEMF-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919127306A GB9127306D0 (en) | 1991-12-23 | 1991-12-23 | Therapeutic agents |
| CN93109559A CN1045291C (zh) | 1991-12-23 | 1993-06-26 | 制备被取代的四氢异喹啉化合物的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI9200410A SI9200410A (en) | 1993-09-30 |
| SI9200410B true SI9200410B (sl) | 2002-02-28 |
Family
ID=36822306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9200410A SI9200410B (sl) | 1991-12-23 | 1992-12-22 | Nove tetrahidroizokinolinove spojine |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5519034A (de) |
| EP (1) | EP0618900B1 (de) |
| JP (1) | JP2642244B2 (de) |
| CN (1) | CN1045291C (de) |
| AT (1) | ATE150015T1 (de) |
| AU (1) | AU662584B2 (de) |
| BG (1) | BG62326B1 (de) |
| CA (1) | CA2126308A1 (de) |
| CZ (1) | CZ282869B6 (de) |
| DE (1) | DE69218248T2 (de) |
| DK (1) | DK0618900T3 (de) |
| ES (1) | ES2098721T3 (de) |
| FI (1) | FI105401B (de) |
| GB (1) | GB9127306D0 (de) |
| GR (1) | GR3023568T3 (de) |
| HR (1) | HRP921458B1 (de) |
| HU (2) | HUT70495A (de) |
| IL (1) | IL104170A (de) |
| IN (1) | IN174437B (de) |
| MX (1) | MX9207495A (de) |
| NO (1) | NO301474B1 (de) |
| NZ (1) | NZ246155A (de) |
| PL (1) | PL173944B1 (de) |
| RO (1) | RO114790B1 (de) |
| RU (1) | RU2122999C1 (de) |
| SI (1) | SI9200410B (de) |
| SK (1) | SK280318B6 (de) |
| WO (1) | WO1993013073A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ290661B6 (cs) * | 1993-06-22 | 2002-09-11 | Knoll Aktiengesellschaft | Tetrahydroisochinolinová sloučenina, způsob její přípravy, farmaceutický prostředek s jejím obsahem a použití |
| US5389638A (en) * | 1993-09-10 | 1995-02-14 | Abbott Laboratories | Tetrahydroisoquinolines as alpha-2 antagonists and biogenic amine uptake inhibitors |
| MX9709914A (es) * | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos. |
| GB9524681D0 (en) * | 1995-12-02 | 1996-01-31 | Knoll Ag | Chemical process |
| JP2000507569A (ja) * | 1996-03-29 | 2000-06-20 | 日本ワイスレダリー株式会社 | 抗精神病薬ならびに鎮痛薬を製造するための、１，１―ジアルキル―１，２，３，４―テトラヒドロイソキノリンの使用 |
| EP1023269A4 (de) * | 1997-09-30 | 2001-06-27 | Molecular Design Int | Beta3-adrenoreceptor-agonisten, agonist-zubereitungen und verfahren zu ihrer verwendung |
| US6410527B1 (en) * | 1998-03-02 | 2002-06-25 | Schering Corporation | Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism |
| US5919794A (en) * | 1998-05-11 | 1999-07-06 | Virginia Commonwealth University | Methods of using pharmaceutical tetrahydroisoquinolines |
| GB0012214D0 (en) * | 2000-05-19 | 2000-07-12 | Merck Sharp & Dohme | Therapeutic agents |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| US6593341B2 (en) | 2001-03-29 | 2003-07-15 | Molecular Design International, Inc. | β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same |
| WO2003007959A1 (en) * | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| US6596734B1 (en) | 2002-10-11 | 2003-07-22 | Molecular Design International, Inc. | Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists |
| ES2239196T3 (es) * | 2002-12-02 | 2005-09-16 | Schwarz Pharma Ag | Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson. |
| ATE450513T1 (de) * | 2004-11-04 | 2009-12-15 | Mallinckrodt Inc | Opiatzwischenprodukte und syntheseverfahren |
| US7511060B2 (en) | 2005-10-21 | 2009-03-31 | Mallinckrodt Inc. | Opiate intermediates and methods of synthesis |
| US7622586B2 (en) * | 2005-10-21 | 2009-11-24 | Mallinckrodt Inc. | Opiate intermediates and methods of synthesis |
| CN102083797B (zh) * | 2008-04-01 | 2014-06-04 | Abbvie公司 | 四氢异喹啉、含有它们的药物组合物和它们在治疗中的用途 |
| US20090312558A1 (en) * | 2008-06-13 | 2009-12-17 | Reliance Life Sciences Pvt. Ltd. | Process for the preparation of arylcyclopropoane carboxylic carbonitriles, and compounds derived therefrom |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| JP2014521682A (ja) | 2011-08-05 | 2014-08-28 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノクロマン、アミノチオクロマンおよびアミノ−１，２，３，４−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、ならびに治療におけるこれらの使用 |
| WO2013072520A1 (en) | 2011-11-18 | 2013-05-23 | AbbVie Deutschland GmbH & Co. KG | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| LT2872145T (lt) | 2012-07-12 | 2022-06-27 | Emalex Biosciences, Inc. | Sujungti benzazepinai tureto sindromui gydyti |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| KR101802048B1 (ko) * | 2013-04-02 | 2017-12-28 | 안지 파마슈티컬 코퍼레이션 리미티드 | 항신경퇴행성제로서의 다작용성 퀴놀린 유도체 |
| CN103435545B (zh) * | 2013-08-14 | 2015-10-07 | 中国药科大学 | 四氢异喹啉季铵盐类衍生物、其制备方法及其镇痛用途 |
| EP3057958B1 (de) | 2013-10-17 | 2019-05-01 | AbbVie Deutschland GmbH & Co. KG | Aminotetralin- und aminoindanderivate, pharmazeutische zusammensetzungen damit und deren verwendung in der therapie |
| CA2924689A1 (en) | 2013-10-17 | 2015-04-23 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| PL3057595T3 (pl) | 2013-10-18 | 2021-03-08 | Emalex Biosciences, Inc. | Skondensowane benzazepiny do leczenia jąkania |
| WO2019099294A1 (en) | 2017-11-14 | 2019-05-23 | Merck Sharp & Dohme Corp. | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| AR113878A1 (es) | 2017-11-14 | 2020-06-24 | Merck Sharp & Dohme | Compuestos de biarilo sustituido como inhibidores de indolamina 2,3-dioxigenasa (ido) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR868733A (fr) * | 1939-10-14 | 1942-01-14 | Troponwerke Dinklage & Co | Procédé pour la fabrication des composés d'isoquinoleine |
| US3717639A (en) * | 1967-05-04 | 1973-02-20 | Little Inc A | Process for the preparation of 1-(2-nitro-3,4-di-lower-alkoxybenzyl)isoquinolines |
| US3755330A (en) * | 1967-08-25 | 1973-08-28 | Sandoz Ag | 1-{60 -hydroxybenzyl 3-methyl, 1,2,3,4-tetrahydroiso quinolino-2-carbonitriles |
| JPS4933805B1 (de) * | 1969-01-31 | 1974-09-10 | ||
| US3852448A (en) * | 1971-02-04 | 1974-12-03 | Sandoz Ag | N-substituted amino-n-nitroso-aminoacetonitriles for treating hypertension |
| US3872130A (en) * | 1971-09-27 | 1975-03-18 | Mead Johnson & Co | 1-hydroxyisoquinolones |
| US3777026A (en) * | 1972-06-14 | 1973-12-04 | Sandoz Ag | N-substituted amino-n-nitroso-amino-acetonitriles as anti-anginal agents |
| US4013664A (en) * | 1973-06-20 | 1977-03-22 | Research Corporation | Synthesis of hernandaline |
| US4018927A (en) * | 1973-12-17 | 1977-04-19 | The Regents Of The University Of Michigan | Treatment of proliferating skin diseases with papaverine alkaloids |
| US4126615A (en) * | 1975-12-12 | 1978-11-21 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt | Process for the manufacture of pure isoquinoline derivatives |
| US4194044A (en) * | 1976-12-06 | 1980-03-18 | Hoffmann-La Roche Inc. | Process for preparing 3-phenoxy morphinans |
| US4115389A (en) * | 1977-05-02 | 1978-09-19 | Bristol-Myers Company | Process of N-demethylating (-)-1-(p-methoxybenzyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline |
| US4235906A (en) * | 1978-07-21 | 1980-11-25 | Massachusetts General Hospital | Bis-isoquinolinium compounds, compositions and methods of use |
| US4491665A (en) * | 1979-10-19 | 1985-01-01 | Burroughs Wellcome Co. | Method of preparing isomers of bis isoquinolinium compounds |
| US4514569A (en) * | 1982-01-28 | 1985-04-30 | Hendrickson James B | Synthesis of 1-substituted isoquinolines |
| DK704488D0 (da) * | 1988-12-19 | 1988-12-19 | Novo Industri As | Nye n-substituerede azaheterocykliske carboxylsyrer |
| GB8501192D0 (en) * | 1985-01-17 | 1985-02-20 | Boots Co Plc | Therapeutic agents |
| DK8386A (da) * | 1986-01-15 | 1987-07-09 | Tpo Pharmachim | Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme |
| US4737504A (en) * | 1986-07-25 | 1988-04-12 | Ohio State University Research Foundation | 5-fluoro-and 8-fluoro-trimetoquinol compounds and the processes for their preparation |
| US4915879A (en) * | 1986-09-19 | 1990-04-10 | Automatic Liquid Packaging, Inc. | Signal coupling for humidifier container |
| GB8921304D0 (en) * | 1989-09-20 | 1989-11-08 | Wyeth John & Brother Ltd | New method of treatment and heterocyclic compounds used therein |
-
1991
- 1991-12-23 GB GB919127306A patent/GB9127306D0/en active Pending
-
1992
- 1992-12-12 ES ES93900051T patent/ES2098721T3/es not_active Expired - Lifetime
- 1992-12-12 AU AU31586/93A patent/AU662584B2/en not_active Ceased
- 1992-12-12 SK SK751-94A patent/SK280318B6/sk unknown
- 1992-12-12 JP JP5511396A patent/JP2642244B2/ja not_active Expired - Lifetime
- 1992-12-12 AT AT93900051T patent/ATE150015T1/de not_active IP Right Cessation
- 1992-12-12 PL PL92304143A patent/PL173944B1/pl unknown
- 1992-12-12 RO RO94-01028A patent/RO114790B1/ro unknown
- 1992-12-12 RU RU94030499A patent/RU2122999C1/ru active
- 1992-12-12 DK DK93900051.9T patent/DK0618900T3/da active
- 1992-12-12 DE DE69218248T patent/DE69218248T2/de not_active Expired - Fee Related
- 1992-12-12 CZ CZ941534A patent/CZ282869B6/cs not_active IP Right Cessation
- 1992-12-12 US US08/244,368 patent/US5519034A/en not_active Expired - Fee Related
- 1992-12-12 WO PCT/EP1992/002900 patent/WO1993013073A1/en active IP Right Grant
- 1992-12-12 CA CA002126308A patent/CA2126308A1/en not_active Abandoned
- 1992-12-12 EP EP93900051A patent/EP0618900B1/de not_active Expired - Lifetime
- 1992-12-12 HU HU9401878A patent/HUT70495A/hu unknown
- 1992-12-12 NZ NZ246155A patent/NZ246155A/en unknown
- 1992-12-17 IN IN757MA1992 patent/IN174437B/en unknown
- 1992-12-18 IL IL10417092A patent/IL104170A/en not_active IP Right Cessation
- 1992-12-22 SI SI9200410A patent/SI9200410B/sl unknown
- 1992-12-22 HR HR9127306.0A patent/HRP921458B1/xx not_active IP Right Cessation
- 1992-12-22 MX MX9207495A patent/MX9207495A/es not_active IP Right Cessation
-
1993
- 1993-06-26 CN CN93109559A patent/CN1045291C/zh not_active Expired - Fee Related
-
1994
- 1994-05-31 BG BG98822A patent/BG62326B1/bg unknown
- 1994-06-22 FI FI943018A patent/FI105401B/fi active
- 1994-06-22 NO NO942375A patent/NO301474B1/no not_active IP Right Cessation
-
1995
- 1995-06-30 HU HU95P/P00689P patent/HU211302A9/hu unknown
-
1997
- 1997-05-28 GR GR970401221T patent/GR3023568T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9200410B (sl) | Nove tetrahidroizokinolinove spojine | |
| ES2629389T3 (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes de obtención de imágenes | |
| HRP20151197T1 (hr) | Supstituirani derivati dibenzo-azepina i benzo-diazepina, koji su korisni kao inhibitori gama-sekretaze | |
| RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
| KR950701323A (ko) | 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives) | |
| TW200508180A (en) | Therapeutic agents | |
| TW200621772A (en) | Compounds which increase apolipoprotein a-1 production and uses thereof in medicine | |
| HRP20020468B1 (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines | |
| HUP9903330A2 (hu) | Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények | |
| HUP0401898A2 (hu) | 3-Szubsztituált-4-pirimidon-származékok, ezeket tartalmazó gyógyászati készítmények és intermedierjeik | |
| HRP20050708A2 (en) | Piperidine-benzenesulfonamide derivatives | |
| AR067540A1 (es) | Compuesto de aril (isoxazol-4-il-metoxilo) , su uso para preparar un medicamento y composicion farmaceutica que lo comprende | |
| JP2007523152A5 (de) | ||
| KR870002127A (ko) | 니트로메틸렌 유도체의 제조방법 | |
| AR029821A1 (es) | Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento | |
| RU2012103460A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-1Н-ИМИДАЗО{1,2-a}ПИРИМИДИН-5-ОНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В ФАРМАЦИИ | |
| DE50010886D1 (de) | Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung | |
| RU2007101497A (ru) | Алкилзамещенные индолхиноксалины | |
| AR062941A1 (es) | Compuestos para el tratamiento de desordenes metabolicos | |
| AR029461A1 (es) | Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento | |
| RU2004122409A (ru) | Тирозилсодержащие производные и их применение в качестве модуляторов рецепторов р2х7 | |
| KR970706826A (ko) | 포스포디에스테라제 IV 억제제로서의 디아제피노-인돌(Diazepino-Indoles as Phosphodiesterase Ⅳ Inhibitors) | |
| KR880000410A (ko) | 이치환된 피페라진 | |
| FR2858321B1 (fr) | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| PT100386A (pt) | Processo para a preparacao de derivados de pirimidina para aumento da actividade anti-tumoral |